Revolution Medicines, Inc.

This study is testing whether a new oral drug called daraxonrasib works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has a specific genetic change (RAS mutation) and has stopped responding to initial treatments. About 420 …

This study is testing whether a new drug called daraxonrasib, given alone or with standard chemotherapy, works better than chemotherapy alone for people with advanced pancreatic cancer that has spread. About 900 participants will be randomly assigned to receive one of three treat…

This study is testing a new oral medication called RMC-6236 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers, that have specific RAS mutations. The main goals are to find a safe and effective dose and to see if the drug can help control the…

This study is testing new combinations of experimental drugs for people with advanced solid tumors that have specific RAS mutations. Researchers want to see if combining a new type of drug called a RAS(ON) inhibitor with another cancer drug called ivonescimab is safe and can help…

This study is testing new targeted drugs called RAS inhibitors in combination with standard cancer treatments for people with advanced colorectal or pancreatic cancer. The goal is to find safe and effective doses while seeing if these new drug combinations can help control cancer…

This early-stage study is testing a new drug called RMC-5127 in adults with advanced cancers that have a specific genetic change called KRAS G12V. The main goals are to find a safe dose and see how the body processes the drug, both when given alone and when combined with other ca…

This study is testing two new drugs, elironrasib and daraxonrasib, for people with advanced lung, colorectal, or pancreatic cancer that has a specific genetic change called KRAS G12C. The main goals are to find safe doses and see if the drugs, given alone or together, can shrink …

This study is testing whether a new oral drug, daraxonrasib, can help keep pancreatic cancer from coming back after surgery and chemotherapy. It will compare the drug to standard observation (no drug) in 500 patients who have had their tumor surgically removed and completed chemo…

This clinical trial is testing several new experimental drugs designed to target specific genetic mutations (called RAS mutations) found in advanced non-small cell lung cancer. The study will involve 616 adults whose cancer has progressed despite standard treatments. Researchers …